Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases

Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases

Background: Two years into the pandemic, vaccination remains the most effective option to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Preliminary studies suggest vaccination efficacy in patients with inflammatory bowel diseases...

Full description

Bibliographic Details
Main Authors: Jagoda Pokryszka, Angelika Wagner, Ursula Wiedermann, Selma Tobudic, Harald Herkner, Stefan Winkler, Sonja Brehovsky, Walter Reinisch, Gottfried Novacek
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Vaccines
Subjects:
inflammatory bowel disease
SARS-CoV-2
fecal calprotectin
COVID-19 vaccine
Online Access:https://www.mdpi.com/2076-393X/10/5/759

Internet

https://www.mdpi.com/2076-393X/10/5/759

Similar Items